Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of trigolutesins A in the treatment of renal insufficiency

A technology for renal insufficiency, applied in the application field of Trigolutesins A in the treatment of renal insufficiency drugs, can solve the problems of large toxic and side effects, high price, dependence on imports, etc., and achieves the effect of strong therapeutic activity and outstanding substantive characteristics.

Active Publication Date: 2015-09-16
湖北康肽药业有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Benazepril and Losartan are currently clinically used to treat renal insufficiency, but they mainly rely on imports. These drugs are expensive and have relatively high toxicity and side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trigolutesins A in the treatment of renal insufficiency
  • Application of trigolutesins A in the treatment of renal insufficiency
  • Application of trigolutesins A in the treatment of renal insufficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of the compound Trigolutesins A tablet involved in the present invention:

[0016] Take 5 grams of compound Trigolutesins A and add 195 grams of dextrin, mix well, and make 1000 tablets by conventional tableting.

Embodiment 2

[0017] Embodiment 2: Preparation of the compound Trigolutesins A capsules involved in the present invention:

[0018] Take 5 grams of compound Trigolutesins A, add 195 grams of starch, mix well, pack into capsules and make 1000 capsules.

[0019] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0020] Experimental example 1: Study on the effect of Trigolutesins A on the acute kidney injury model in mice

[0021] 1. Establishment of cisplatin-induced acute kidney injury model in mice: male Kunming KM mice, 16-18 g, were randomly divided into solvent control group, cisplatin model group and administration group according to body weight, a total of 6 groups, each group 8 only. The control group was intraperitoneally injected with normal saline, and cisplatin was dissolved in normal saline and injected intraperitoneally at 7 mg / kg. The compound of the present invention was orally administered 2 days before the injection of cisplatin, once a day for a total of five times; the positive control drug Benazepril (K) was orally administered at the same time as the injection of cisplatin, once a day for a total of five times. Three times of administration (administration started 2 days before the injection of cisplatin is less effective than simultaneous administration, and th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of Trigolutesins A in medicine for prevention and / or treatment of renal insufficiency, which belongs to the technical field of new application of medicines and is disclosed for the first time; as the skeleton type belongs to a brand new skeleton type, and the renal insufficiency treatment activity is high, the Trigolutesins A has outstanding substantive features and has an obvious progress in the prevention and treatment of dental ulcer renal insufficiency.

Description

technical field [0001] The present invention relates to a new application of compound Trigolutesins A, in particular to the application of Trigolutesins A in the preparation of medicines for treating renal insufficiency. Background technique [0002] Chronic kidney disease (including various chronic nephritis, diabetic nephropathy and hypertensive renal damage, etc.) is the most common chronic refractory disease. Renal tissue lesions will gradually progress from early lesions to advanced lesions of glomerulosclerosis and / or interrenal fibrosis. If not treated effectively, it will eventually lead to chronic renal insufficiency and irreversible end-stage renal failure (ie uremia). Benazepril and Losartan are currently clinically used to treat renal insufficiency, but they mainly rely on imports. These drugs are expensive and have relatively high toxicity and side effects. Such as causing some patients hyperkalemia, insurmountable cough, blood pressure lowering effect is not ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4741A61P13/12
Inventor 解彩丽刘国华孙岩
Owner 湖北康肽药业有限公司